MGH Main Web 
Brain Tumor Center HomeBrain Tumor Center HomeBTC and Affiliates
 
MGH BTC Home
- About Us
- Appointments
- BTC Textbook
- Consultations
- Education
- Fellowship in the BTC
- New Treatments
- News, etc.
- Research
- Services
- Spine Tumor Clinic
- Staff
- Support Groups
- Therapies
- Tumor Types
- BT Links
Search BTC Web
 
Brain Tumor Webs
- Brain Tumor Center
- Brain Tumor Research
- Neuro-Oncology
- Neurosurgery
- Neurology
- Radiation Oncology
Pappas Center @ MGH
Neuro-Oncology @ MGHNeurosurgery @ MGHNeurology @ MGHRadiation Oncology @ MGH
[Divider]

New Treatments

Chemotherapy trials  |  Radiation oncology trials | Glossary of terms

The MGH Brain Tumor Center is dedicated to the discovery of better treatments for patients with brain tumors. As a result, patients at the center may have the opportunity to participate in clinical trials. To find out more about clinical trials, review this page or call the Center at 617.724.8770.

Chemotherapy Trials

The Brain Tumor Center conducts studies of many new treatments. Some of these studies are organized by the Center's investigators working together with pharmaceutical companies, others are performed by consortia of research hospitals in the US and Canada. The MGH Brain Tumor Center is a founding member of the National Cancer Institute-sponsored cooperative clinical trials group called New Approaches to Brain Tumor Therapy (NABTT).

Current Clinical Trials at the MGH Brain Tumor Center

Updated 10/17/03

Agent/Investigator Study Type Description Status

Radiation Oncology Trials

The MGH is a participating institution in trials sponsored by the Radiation Therapy Oncology Group (RTOG).

Current Clinical Trials at the MGH Brain Tumor Center

Agent Study Type Description Status


Glossary of Terms

Some definitions of terms used in clinical trials of new brain tumor treatments may be helpful.

Phase I - A small trial, typically with only 10 to 12 patients, designed to test the toxicity of increasing doses of a new agent.

Phase II - Larger trial to assess whether a agent from the Phase I level can effectively treat a tumor.

Phase III - Very large trial designed to compare how a new agent from the Phase II level compares to the best currently available agent(s).

Neoadjuvant - Agent is administed after biospy (or surgery), but prior to irradiation.

Adjuvant- Agent is administered after biospy (or surgery) and completion of irradiation.

Recurrent - Agent is administered at the time of tumor progression or recurrence.

Advancing the Specialized Care of Individuals with Brain Tumors
US News Home

APPOINTMENTS & REFERRALS

MGH Brain Tumor Center
Yawkey Building 9th Floor
Boston, Massachusetts,  02114
[Divider]
[Divider]
Patients & Families with questions about referrals, consultations or appointments may contact:
Telephone: 617.724.8770
Fax: 617.724.8769

PHYSICIANS' INFO SERVICE

Physicians with
questions may contact:
Tracy Batchelor, M.D.
Executive Director,
MGH Brain Tumor Center
 
Harvard Medical School
Mass General Hospital
MassGeneral.org
MGH Cancer Center
NS @ MGHNS Diagnosis @ MGH
Disclaimer About Medical Information: The information and reference materials contained herein is intended solely for the information of the reader. It should not be used for treatment purposes, but rather for discussion with the patient's own physician. All visitors to this and associated sites from the Neurosurgical Service at MGH agree to read and abide by the the complete terms of legal agreement found at the Neurosurgery "disclaimer & legal agreement." See also: the MGH Disclaimer, the MGH Privacy Policy, and the MGH Interactive Program Disclaimer - Copyright 2008 MGH Neurosurgical Service - All Rights Reserved. System Info Contact: C.Owen
electronswebsBTCReferral@Neurosurgery.MassGeneral.org Neurosurgery@MGH IntraNet
Brain Tumor Center @ MGH MassGeneralWeb Partners Health Care Harvard Medical School